Cole, A., Lundqvist, A., Lorgelly, P., Norrlid, H., Karlsberg Schaffer, S., Lewis, F., Hernandez-Villafuerte, K., Lindgren, P., Garau, M., Welin, K-O., Bianchi, S., Althin, R., O’Neill, P., Persson, U., and Towse, A.
The economic burden that cancer poses on our society is staggering – 25 million years of healthy life lost, at cost of €126 billion including €52 billion in lost productivity – and continues to grow with the ageing of the population. It is imperative, in light of growing financial pressures on our health care systems, that we find ways to make the best use of available resources to deliver high quality cancer care to patients.
Marsden, G., Martin, A., Zamora, B., Exley, J., Sussex, J. and Towse, A.
The Oxford Academic Health Science Network (Oxford AHSN) wishes to demonstrate the value of the various projects and programmes that the network has developed and implemented since it was established in 2013.
Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled "New Age Decision Making in HTA: Is It Applicable in Asia?". To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic.
Cole, A., Chan, A., Mujoomdar, M., Pichler, F. and Towse, A.
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled "How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?" and was chaired by Franz Pichler (Eli Lilly & Company).
This OHE Seminar Briefing summarises a seminar given by Professor Luigi Siciliani on waiting time policies in the health sector from an international perspective, and highlights which policies have worked well in the last decade in OECD countries. Professor Siciliani also touches on methods for comparing waiting times internationally and where the UK stands in the international figures. Finally, the Briefing discusses waiting time inequality by socioeconomic status.
Brockis, E., Marsden, G., Cole, A., and Devlin, N.
NICE’s decisions exert an influence on the allocation of fixed NHS budgets, but decisions for different types of health interventions (for example drugs and devices) are handled via different ‘programmes’ within NICE.
Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A.
This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) to decide which new medicines to recommend for use in the NHS, and the direction of future research in this area.
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.
Feng, Y., Devlin, N., Shah, K., Mulhern, B. and Van Hout, B.
Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version. Any use of the content of these materials is the sole responsibility of the user.
Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.
Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version.